Artax Biopharma
Total Raised
$55.18MInvestors Count
7Deal Terms
2Funding, Valuation & Revenue
9 Fundings
Artax Biopharma has raised $55.18M over 9 rounds.
Artax Biopharma's latest funding round was a Convertible Note - II for $3M on July 29, 2025.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
7/29/2025 | Convertible Note - II | $3M | Undisclosed Investors | 1 | ||
8/6/2024 | Convertible Note | |||||
1/3/2022 | Series C | |||||
2/26/2021 | Debt - II | |||||
4/29/2020 | Series B - III |
Date | 7/29/2025 | 8/6/2024 | 1/3/2022 | 2/26/2021 | 4/29/2020 |
|---|---|---|---|---|---|
Round | Convertible Note - II | Convertible Note | Series C | Debt - II | Series B - III |
Amount | $3M | ||||
Investors | Undisclosed Investors | ||||
Valuation | |||||
Revenue | |||||
Sources | 1 |
Artax Biopharma Deal Terms
2 Deal Terms
Artax Biopharma's deal structure is available for 2 funding rounds, including their Series B from September 22, 2015.
Round | Series B | Series A |
|---|---|---|
Funding Date | ||
Pre-Money Valuation | ||
Post-Money Valuation | ||
Amount Raised | ||
Shares Authorized | ||
Issuance Price | ||
Dividend Rate | ||
Liquidation Preferences | ||
Liquidation Price | ||
Participation | ||
Conversion Price | ||
Anti Dilution | ||
General Voting | ||
Board Voting | ||
Par Value |
Round | Funding Date | Pre-Money Valuation | Post-Money Valuation | Amount Raised | Shares Authorized | Issuance Price | Dividend Rate | Liquidation Preferences | Liquidation Price | Participation | Conversion Price | Anti Dilution | General Voting | Board Voting | Par Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Series B | |||||||||||||||
Series A |
Artax Biopharma Investors
7 Investors
Artax Biopharma has 7 investors. Advent Life Sciences invested in Artax Biopharma's Convertible Note funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
9/22/2015 | 8/6/2024 | 5 Series B, Series B - II (2019), Series B - III (2020), Series C (2022), Convertible Note (2024) | Venture Capital | United Kingdom | ||
Venture Capital | Spain | |||||
Corporation | Indiana | |||||
Angel Investor (Individual) | Massachusetts | |||||
Venture Capital | Sweden |
First funding | 9/22/2015 | ||||
|---|---|---|---|---|---|
Last Funding | 8/6/2024 | ||||
Investor | |||||
Rounds | 5 Series B, Series B - II (2019), Series B - III (2020), Series C (2022), Convertible Note (2024) | ||||
Board Seats | |||||
Type | Venture Capital | Venture Capital | Corporation | Angel Investor (Individual) | Venture Capital |
Location | United Kingdom | Spain | Indiana | Massachusetts | Sweden |
Loading...